Chris Choe

Capital International SARL is an investment management firm headquartered in Geneva, Switzerland. The firm was founded in 1962 and is a subsidiary of Capital Group International, Inc., ultimately owned by The Capital Group Cos., Inc. in the US. Capital International provides investment management services to individual investors, financial intermediaries, and institutions and consultants.

Goldman Sachs Advisors BV (GSBV) is the wholly owned, Netherlands-based investment management subsidiary of Goldman Sachs Asset Management International Holdings BV, ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) (Goldman Sachs) in the US. Founded in 1994 as ING Investment Management Advisors BV, the firm became NNIP Advisors BV in 2015 following the IPO of NN Group. They changed their name to Goldman Sachs Advisors BV in 2023 after the acquisition of Goldman Sachs to NN Group in 2022. Headquartered in The Hague, GSBV manages a range of assets for institutional and individual clients.

Capital International Ltd. (Capital UK) is the Great Britain-based investment subsidiary of Capital Group International Inc., itself a subsidiary of The Capital Group Cos., Inc. in the US. The firm do-business-as Capital Research & Management Co. (UK Branch). Headquartered in London, Capital UK was founded in 1982 and provides discretionary investment management services to segregated institutional clients in the UK and across Europe.

Banque Syz SA (Banque Syz) is the private banking subsidiary of Swiss banking group Financière Syz & Co. SA. Established in 1996, the firm is headquartered in Geneva and specializes in providing a range of asset management and advisory services including discretionary mandates and a range of Luxembourg-based mutual funds and hedge funds for private investors, high-net worth individuals, institutional clients and independent asset managers.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

Capital International, Inc. (Singapore) (CII-SG) is the Singapore office of US-based Capital International Private Equity Funds, itself a wholly-owned subsidiary of The Capital Group Cos., Inc., a privately-owned holding company based in California. Established in 1989, the Singapore office provides investment management services to institutional clients primarily in Asia, via separate accounts and commingled funds. Their clients include pension funds, banks, financial institutions, endowments, foundations and family offices. CII-SG advises Asian portfolios for funds managed within the parent group, and distributes a large range of investment products managed by the Capital companies. They are also private equity investors.

Capital Research & Management Co., dba Capital World Investors (CWI), is an investment advisor headquartered in Los Angeles, California. The firm is a division of Capital Research & Management Co., which is ultimately owned by the Capital Group of Companies. In 2013, The Capital Group restructured their equity investment group and divided the group based on specific investment objectives rather than around particular products or clients. The investment group is now divided into three independent equity divisions, Capital World Investors, Capital Research Global Investors and Capital International Investors. Each division has the flexibility to manage any of the investment objectives or any of the investment vehicles the Capital Group offers. CWI is the retail entity of the Capital Group.

Capital International, Inc. (Hong Kong) (CII HK) is the investment advisory division of Capital International Inc., ultimately held by US-based The Capital Group Cos., Inc. The firm is headquartered in Hong Kong and was founded in 1983. CII HK provides investment services to a range of clients such as individuals, families, businesses and institutions.

Mimix Biotherapeutics Sàrl is a private company located in Switzerland that develops and commercializes a platform to overcome limitations in tissue engineering, specifically the vascularization challenge and the need for high cell quantities. The Swiss company creates biological architectures with sound using sound-induced morphogenesis, which is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves. The company offers guides for patterning parameters and cells in various hydrogels, including collagen, fibrin, gelatine, and synthetic hydrogels. The company's FastSkin® technology combines micrografting with sound-induced morphogenesis to improve wound care management, addressing a major social burden and unmet clinical need in oncology and chronic wounds treatments. Mimix Biotherapeutics also provides control over cellular and extracellular organization at high spatial resolution to investigate cell-material interactions in vitro models.